UCLTF portfolio company Orchard Therapeutics has announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants that could bring in up to $188 million.
The financing was led by RA Capital Management and attracted new and existing investors Deep Track Capital, Cowen Healthcare Investments, Woodline Partners LP and Zentree Investments Ltd., among others.
“This commitment from top-tier investors is a significant demonstration of confidence ahead of our anticipated regulatory filing for OTL-200 in the U.S. The financing will provide important capital to accelerate the commercialization of Libmeldy and advance the other programs in our HSC gene therapy platform. We believe the deal’s innovative structure provides additional committed capital at progressively higher valuations as OTL-200 advances towards potential regulatory approval in the United States.” Frank Thomas, president and chief operating officer of Orchard Therapeutics.
“This commitment from top-tier investors is a significant demonstration of confidence ahead of our anticipated regulatory filing for OTL-200 in the U.S. The financing will provide important capital to accelerate the commercialization of Libmeldy and advance the other programs in our HSC gene therapy platform. We believe the deal’s innovative structure provides additional committed capital at progressively higher valuations as OTL-200 advances towards potential regulatory approval in the United States.”
Orchard is building on decades of research and advancements in the field of gene therapy to develop potential cures for genetic and other severe diseases.
Read the full story here.
We make UCL’s research physical and life sciences ideas happen.
